autoimmune diseases
Conditions
Interventions
Case series:CAR-NK cells
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Chinese subjects aged 18 to 70 years when signing the informed consent; 2. Expected survival > 12 weeks; 3. Diagnosed with autoimmune disease by physical examination, pathological examination, laboratory examination and imaging, and the therapeutic effect of glucocorticoid and/or immunosuppressive agent is not good; 4. Creatinine < 2.5mg/dl; 5. ALT, AST < 3 times ULN; 6. Bilirubin < 2.0mg/dl; 7. ECOG score 0~1; 8. The patient's peripheral superficial venous blood flow is smooth, which can meet the needs of intravenous drip; 9. Subjects must obtain informed and signed informed consent, indicating that they understand the purpose and procedures of this study and are willing to participate in the study; willing and able to follow the contraindications and restrictions specified in this protocol.
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant (positive blood pregnancy test) or breastfeeding, or women who plan to become pregnant within one year; 2. Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.); 3. The patient has participated in other clinical trials before enrollment and has not passed the washout period; 4. Those with abnormal vital signs and those who cannot cooperate with the inspection; 5. Highly allergic or have a history of severe allergies, especially those allergic to IL-2; 6. Suffering from serious mental illness; 7. The patient has drug abuse/addiction; 8. Subjects with systemic infection or severe local infection requiring anti-infection treatment; 9. Complicated with dysfunction of important organs such as heart, lung, brain, liver and kidney; 10. According to the judgment of the investigator, the patient has other conditions that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety;efficacy;Progression Free Survival; | — |
Countries
China
Contacts
Public ContactCao Jiang
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed